Kevin A. Schulman, MD; L. Elizabeth Rubenstein, BA; Darrell R. Abernethy, MD, PhD; Damon M. Seils, BA; Daniel P. Sulmasy, OFM, MD, PhD
Over the last decade, the number of pharmaceutical benefits managers has increased, and their influence has expanded rapidly. These managers now provide prescription drug coverage to more than 100 million Americans. The effect of pharmaceutical benefits managers on health care delivery remains unclear. We review the development of these organizations, their current role in the delivery of pharmaceutical therapies to patients, and their relationship with pharmaceutical manufacturers. We discuss potential advantages and disadvantages of pharmaceutical benefits manager practices and suggest ways in which these organizations can be made more accountable to the employer groups that hire them.
Kevin A. Schulman, L. Elizabeth Rubenstein, Darrell R. Abernethy, Damon M. Seils, Daniel P. Sulmasy. The Effect of Pharmaceutical Benefits Managers: Is It Being Evaluated?. Ann Intern Med. 1996;124:906–913. doi: 10.7326/0003-4819-124-10-199605150-00008
Download citation file:
Published: Ann Intern Med. 1996;124(10):906-913.
Healthcare Delivery and Policy.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use